# US 2006/0041139 A9 · Substituted alkyl amido piperidines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0041139 A9
- Document ID: US20060041139A9
- Status: Published application
- Kind: A9
- Application number: 10/345,063
- Filed: 2003-01-14
- Published: 2006-02-23
- Earliest claimed: 2001-07-05
- Assignees: Synaptic Pharmaceutical Corporation
- Inventors: Mohammad Marzabadi; John Wetzel; Chien-An Chen; Yu Jiang; Kai Lu
- Web page: https://patentgrep.com/patent/US20060041139A9

## CPC

- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/28: to which a second hetero atom is attached
- C07D 211/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/56: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

## Claims

### Claim 1

A compound having the structure:
wherein each R1 is independently hydrogen; —F; —Cl; —Br; —I; —CN; —NO2; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl; C3-C7 cycloalkyl or C5-C7 cycloalkenyl; aryl; heteroaryl; —N(R5)2; —(CH2)mOR5; —COR5; —CO2R5; —OCOR5; —CON(R5)2; —N(R5)COR5; —N(R5)CON(R5)2; —OCON(R5)2 or —N(R5)CO2R5;
wherein R2 and R3 are independently hydrogen; —F; —Cl; —Br; —I; —CN; —(CH2)mOR5; —(CH2)mSR5; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R1; or
wherein R2 and R3 together can be —(CH2)p—;
wherein R4 is straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, C3-C6 cycloalkyl, —N(R5)2 or —(CH2)mOR5;
wherein each R5 is independently hydrogen; aryl; heteroaryl or straight chained or branched C1-C7 alkyl, wherein the alkyl may be substituted with aryl or heteroaryl;
wherein each R6 is independently hydrogen; straight chained or branched C1-C7 alkyl;
wherein each R7 is independently hydrogen; phenyl or straight chained or branched C1-C7 alkyl, wherein the alkyl may be substituted with phenyl;
wherein each m is independently an integer from 0 to 5 inclusive;
wherein n is an integer from 1 to 5 inclusive;
wherein p is an integer from 2 to 7 inclusive;
wherein q is an integer from 0 to 2 inclusive;
wherein X is CH or N;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each R1 is independently hydrogen; straight chained or branched C1-C7 alkyl; —F; —Cl; —Br; —I; —CN; —NO2; straight chained or branched C1-C4 alkyl or polyfluoroalkyl; —(CH2)mOR5; —COR5; —CO2R5; —OCOR5; —CON(R5)2; —N(R5)COR5 or —N(R5)CON(R5)2;
wherein R2 and R3 are independently hydrogen; —F; —Cl; —Br; —I; —CN; —(CH2)mSR5; straight chained or branched C1-C7 alkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R1; or
wherein R2 and R3 together can be —(CH2)p—;
wherein R4 is straight chained or branched C1-C7 alkyl; C3-C6 cycloalkyl; —N (R5)2 or —(CH2)mOR5;
wherein each R5 is independently hydrogen or straight chained or branched C1-C3 alkyl, wherein the alkyl may be substituted with phenyl;
wherein m is 0 to 3;
wherein n is 1 to 3;
wherein p is an integer from 2 to 5 inclusive;
wherein q is 0; and
wherein X is CH.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the compound has the following structure:

### Claim 4 (depends on 3)

The compound of claim 3, wherein the compound has the following structure:

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is hydrogen; —F; —Cl; —Br; —I or straight chained or branched C1-C7 alkyl; and
wherein R2 is hydrogen or straight chained or branched C1-C7 alkyl.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R4 is straight chained or branched C1-C7 alkyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the compound has the structure:

### Claim 8 (depends on 7)

The compound of claim 7, wherein the compound is selected from the group consisting of:

### Claim 9 (depends on 7)

The compound of claim 7, wherein the compound is selected from the group consisting of:

### Claim 10 (depends on 7)

The compound of claim 7, wherein the compound is selected from the group consisting of:

### Claim 11 (depends on 4)

The compound of claim 4, wherein R4 is C3-C6 cycloalkyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein the compound is selected from the group consisting of:

### Claim 13 (depends on 2)

The compound of claim 2, wherein R2 and R3 are independently hydrogen; —F; —Br or straight chained or branched C1-C7 alkyl.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R2 and R3 are independently hydrogen or straight chained or branched C1-C7 alkyl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the compound has the structure:

### Claim 16 (depends on 13)

The compound of claim 13, wherein R2 and R3 are independently hydrogen; —F or —Br.

### Claim 17 (depends on 16)

The compound of claim 16, wherein the compound has the structure:

### Claim 18 (depends on 2)

The compound of claim 2, wherein R2 and R3 together are —(CH2)p—;

### Claim 19 (depends on 18)

The compound of claim 18, wherein the compound has the structure:

### Claim 20 (depends on 19)

The compound of claim 19, wherein R4 is straight chained or branched C1-C7 alkyl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein the compound is selected from the group consisting of:

### Claim 22 (depends on 20)

The compound of claim 20, wherein the compound is selected from the group consisting of:

### Claim 23 (depends on 2)

The compound of claim 2, wherein the compound has the following structure:

### Claim 24 (depends on 23)

The compound of claim 23, wherein the compound has the following structure:

### Claim 25 (depends on 24)

The compound of claim 24, wherein the compound has the structure:

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is enantiomerically pure.

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is diastereomerically pure.

### Claim 28 (depends on 26)

The compound of claim 26, wherein the compound is enantiomerically and diastereomerically pure.

### Claim 29 (depends on 27)

The compound of claim 27, wherein the compound is enantiomerically and diastereomerically pure.

### Claim 30 (depends on 1)

A pharmaceutical composition that comprises a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 1)

A pharmaceutical composition made by admixing a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 32 (depends on 1)

A process for making a pharmaceutical composition comprising admixing a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 1)

A method of treating a subject suffering from a disorder mediated by the MCH1 receptor comprising administering to a subject in need of such treatment a therapeutically effective amount of the compound of claim 1.

### Claim 34 (depends on 33)

The method of claim 33, wherein the therapeutically effective amount is between about 0.03 and about 300 mg.

### Claim 35 (depends on 33)

The method of claim 33, wherein the disorder is depression.

### Claim 36 (depends on 33)

The method of claim 33, wherein the disorder is anxiety.

### Claim 37 (depends on 33)

The method of claim 33, wherein the disorder is obesity.

### Claim 38 (depends on 33)

The method of claim 33, wherein the disorder is urge incontinence.

### Claim 39 (depends on 1)

A method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence or obesity, comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 40 (depends on 39)

The method of claim 39, wherein the therapeutically effective amount is between about 0.03 and about 300 mg.

### Claim 41 (depends on 39)

The method of claim 39, wherein the disorder is depression.

### Claim 42 (depends on 39)

The method of claim 39, wherein the disorder is anxiety.

### Claim 43 (depends on 39)

The method of claim 39, wherein the disorder is obesity.

### Claim 44 (depends on 39)

The method of claim 39, wherein the disorder is urge incontinence.
